Clinical Trials
Harbour BioMed Announces the Phase I Study Results in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors
Harbour BioMed
PR-10-24-NI-39Oct 11, 2024
Licensing
Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery
Harbour BioMed
PR-M05-19-NI-088May 31, 2019
Agreement
Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
Glenmark Pharmaceuticals
PR-M08-18-NI-050Aug 13, 2018